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Abstract
Background: The treatment of aneurysmal bone cysts (ABCs) has evolved and less invasive methods have been
tried. Denosumab is a monoclonal antibody which inhibits osteoclasts. It has been shown to be effective in giant
cell tumour of bone (GCT) of bone and hence promises some effect also in ABC. We report on 6 patients treated
with Denosumab and compare our results to the cases already published.
Methods: Data of 6 patients with ABCs and patients whose treatment included Denosumab were retrospectively
analyzed. Denosumab was used at a dose of 120 mg on days 1, 8, 15 and 29, and every 4 weeks thereafter. In some
of these patients the dose was reduced at the end of the treatment. Clinical and radiological responses were
evaluated.
Results: In 4 female and 2 male patients with a mean age of 17 years (range: 6–30 years) the lesions were located
in the sacrum (2), in distal radius, distal femur, talus and pelvis. One of the sacral lesions healed after 12 months and
has stayed stable for 3 years since. The second patient received 2 years of therapy with recalcification, but recurred
1 year later and is under renewed therapy. The pelvic lesion improved but recurred. This patient has a 13-years
history of intermittent therapy including surgery, two pregnancies and remains in a stable situation. The lesion of
the talus did not improve with Denosumab after surgery and was complicated by destruction of the ankle joint
with osteoarthritis. Recurrent lesions of the distal femur and the distal radius, previously treated by curettage and
bone grafting healed under Denosumab and have remained stable for 2 and 3 years, respectively. One case of
severe hypercalcemia was observed in a 7-year old child 6 months after discontinuation of Denosumab.
Conclusion: Denosumab provides a treatment option for ABCs in anatomically critical locations. Adjuvant
application might reduce the rate of local recurrence. In young patients, severe rebound hypercalcemia months
after discontinuation of Denosumab may occur.
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Background
Aneurysmal bone cysts (ABC) are considered benign yet
locally aggressive lesions with a relevant potential for local
recurrence. They typically appear in the metaphyses of the
long bones and in the vertebral column and were first de-
scribed by Jaffe and Liechtenstein in 1942 [1–3]. ABC’s
are most often seen in children and young adults with no
gender predilection. They are lytic, blood-filled, separated
by fibrous septa and with histopathology typically showing
fibroblasts, osteoclast-type giant cells and reactive woven
bone [4].
ABC(s) were originally thought to be reactive in nature,
caused by a circulatory abnormality leading to an increased
venous pressure and resulting in dilation of the intraosseous
vascular network [5, 6]. In 1999, Panoutsakopoulos et al.
demonstrated a balanced chromosomal translocation t(16;
17)(q22;p13) as a cytogenetic abnormality in primary
aneurysmal bone cyst [7] involving the ubiquitin carboxyl-
terminal hydrolase 6 (USP6) gene, located on chromosome
17p13. Since then, the neoplastic nature of ABC has been
established and the USP6 translocation has since been found
in approximately 75% of cases [8]. In differentiating primary
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ABC’s from secondary lesions or other tumors such as tel-
angiectatic osteosarcoma this may be an option in selected
cases. This particular translocation enhances the production
of TRE17, a protease which leads to increased matrix metal-
loproteinase (MMP)-9 and increased MMP-10 activity [9].
This in turn is associated not only with blocking osteoblastic
maturation via an autocrine mechanism involving bone
morphogenetic dysregulation, but also increased release of
VEGF (Vascular Endothelial Growth Factor) thus enhancing
vascularization [10].
The treatment of ABC has changed over the years. Due
to its often mutilating character, resection is not an ac-
ceptable option in most of the cases leaving intralesional
procedures such as curettage as the standard of care [11].
Less invasive methods such as aggressive biopsy (“Cur-
opsy”) [12], selective arterial embolization [13, 14], sclero-
therapy with ethibloc or polidocanol [15] have been tried.
Denosumab is a human monoclonal antibody which
binds specifically to the cytokine receptor activator of
nuclear factor-kappa B ligand (RANKL) [16]. This pre-
vents RANKL from activating the RANK receptor of os-
teoclasts, inhibiting osteoclast function. Denosumab is
highly effective in giant cell tumour of bone (GCT) and
therefore similar effects in principle could be hoped for
in ABC, which has distinct similarities to GCT [17]. Up
to now no protocol or treatment recommendation for
the use of denosumab in ABC exists.
To our best knowledge, 2 case series (with 9 patients
each) have previously been published [18–20] with an
additional 11 cases having been published as individual
case reports [20–29].
The aim of this study is to report our results from a
series of 6 patients and to compare our experience to
the data already published.
Methods
Retrospectively all 65 patients with ABCs treated at our
institution between 1982 and 2014 were analyzed with
data having been collected in a prospective fashion. In 6
cases, Denosumab was used off-label in accordance to
the established protocol in giant cell tumor (GCT) of
bone [30]. The indications had been expected unreason-
able morbidity of surgical treatment either in a primary
or in a recurrent lesion or in an adjuvant setting after
surgery for local recurrence. This study was approved by
the ethics committee of our faculty (#18–373). Written
consent was obtained from all patients included in this
study. Denosumab was administered subcutaneously at a
dose of 120 mg on days 1, 8, 15 and 29, and every 4
weeks afterwards. This scheme is later referred to as the
so-called adult regimen. In a 6-year old boy, the dose
was reduced as is described below. In some of the pa-
tients, the dose was reduced towards the end of the
treatment as also described below. Calcium 500mg and
Vitamin D 1000 IU were supplemented on a daily basis.
Clinical data was collected from the patients charts.
Routine follow-up investigations such as magnetic res-
onance imaging (MRI) or radiographs and in specific
cases also computed tomography (CT) were performed
every 3 months in the first year of therapy, every 6
months in the second year and then based on individual
decision. But as described in the literature ABCs should
be considered as completely healed if recurrence does
not occur within 2 years after the end of therapy [13].
Results
From 2011 to 2018, 6 patients (4 female and 2 male)
with histologically proven ABCs were treated with Deno-
sumab. The mean age was 17 years (range: 6–30 years).
Two lesions were located in the sacrum, one each in dis-
tal radius, distal femur, talus and pelvis. Pain was the
leading symptom in all patients with a mean duration of
14 months (1–42months) prior to diagnosis.
The two patients with sacral ABCs underwent needle
biopsies prior to initiating treatment.
Case 1
In this 6-year-old boy, the Denosumab dosage regimen was
adapted from a published trial of Densoumab in GCT by
using 50% of the proposed adult dosage (60mg every 4
weeks with two additional doses on days 8 and 15). Two
months after the initiation of treatment the child was free
of pain. A second CT-scan showed the ABC constant in
size but with increasing bone density at the margins of the
lesion (Fig. 1). At this point, the parents requested an add-
itional embolization, but angiography showed no tumour
vessels and no arterial irregularities and only a minimal
embolization with 0.5ml silicon spheres was performed.
The Denosumab application was continued. After 1 year of
treatment, the child was free of pain with normal growth
and teething. The latest CT-scan showed an impressive
growth of bone starting from the margins of the lesion with
remnants of the cyst on the left and with complete filling of
the defect on the right side. The treatment was stopped
and a follow-up examination was scheduled for 12months
later. In October 2015, another CT scans showed nearly
complete healing of the cyst. But as a consequence of
Denosumab discontinuation, a severe rebound hypercalce-
mia had developed 6months after the end of therapy and
made intensive care treatment necessary.
Case 2
An 18-year old male, also with a sacral ABC had an injec-
tion with polidocanol and an embolization not leading to
any improvement. Threemonths later, Denosumab was
initiated using the above mentioned adult regimen. After 1
year with clinical and radiological success, the dosage was
gradually reduced and after 2 years Denosumab was
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stopped. One year later he developed a local recurrence as
evidenced by MRI and Denosumab was restarted. 1 ½ year
later with again radiologically confirmed recalcification the
dosage was again reduced.
Case 3
A 30-year old lady with a very large ABC of the left pel-
vis had curettage and bone grafting after CT-guided bi-
opsy and developed a recurrence 1 year later. Again
curettage and bone grafting was performed resulting in a
second recurrence, 3 ½ year later. Denosumab was then
initiated using the adult regimen. After 5 months, a clear
response was documented, but after 8 months despite
Denosumab, local recurrence was evident and due to the
reduced stability around the acetabulum, curettage and
bone grafting were again performed. Three months later,
she became pregnant and 1 1/2 years after the previous
surgery, another recurrence was seen and Denosumab
was restarted after cessation of breast feeding 5months
after the diagnosis of LR. After 18 months, the situation
was stable and the patient decided for a second preg-
nancy with cessation of Denosumab. Three years later
and after an uncomplicated second pregnancy with
twins, a recurrence was again obvious. A needle biopsy
was performed that excluded GCT and confirmed ABC.
Denosumab was started again resulting in partial scler-
osing of the lesion. The dosage of Denosumab has since
been reduced to 120 mg every 2 months.
Case 4
In a 16-year old female after a second recurrence at the
talus treated with bone grafting, Denosumab was used
for 1 year with 120 mg per month leading to a stable
situation. Two years later the lesion again recurred but
now as a ganglioma due to the secondary destruction of
the joint surface. In order to preserve all options for fu-
ture treatment of the ankle joint, repeat curettage and
bone grafting were performed.
Case 5
In a 15-year old female the lesion at the distal radius
was treated with polidocanol injections and a simultan-
eous biopsy at the time of the first injection. Due to pro-
gression subsequently curettage and bone grafting were
performed. Three months later due to recurrence the
procedure had to be repeated (Fig. 2). Denosumab was
then initiated in the adult regimen for 6 months leading
to healing of the lesion with the latest follow-up now 3
years after that point.
Case 6
In a 16-year old female after biopsy the lesion at the distal
femur was treated with an embolization that had no effect
and resulted in further growth of the cyst. Curettage and
bone grafting were performed showing progressive local
recurrence 3 and 5months after surgery. Denosumab was
begun according to the adult regimen for 1 year followed
by 120mg every 2 months for 6months and by 120mg
Fig. 1 a, b: CT-scan (A) showing the massive destruction of the left and also in parts the right sacrum at the levels S1 and S2. The blood filling of
the cyst is clearly visible as fluid-fluid levels in the T2-weighted MRI image (b). c: CT-scan 2 months after initiation of treatment showing
increasing bone density at the margins of the lesion. d: CT-scan one after 1 year of treatment proofing the total bone restoration in the right and
the impressive gain of bone at the left sacrum
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every 3months for another 6months. Under this therapy,
the lesion healed without any signs of recurrence and has
been stable now for 2 years.
So in total Denosumab healed one sacral lesion and
stabilized a second with recurrence after cessation and
recalcification after re-establishment of therapy. The pel-
vic lesion improved but recurred after cessation of ther-
apy. This particular patient has a 13-years history of
intermittent treatment with two pregnancies in between
and is currently in a stable situation. The lesion of the
talus did not improve but was complicated by secondary
osteoarthritic destruction. The recurrencies of the distal
femoral and the distal radius lesion after curettage and
bone grafting healed with Denosumab and have
remained s for 2 and 3 years after cessation of therapy.
Discussion
ABC are benign but locally aggressive lesions. Wide resec-
tion is not an option for the majority of patients because of
the resulting disability. So intralesional curettage with or
without bone grafting is still the predominantly used ther-
apy, but carries a risk of local recurrence of about 20% [3].
Over the years, less invasive procedures have been propa-
gated. Ethibloc, an alcoholic solution of a fibrogenic and
thrombogenic agent proved to be effective with repeated in-
jections but in some cases showed severe side effects [31].
In a randomized study with 94 patients, repeated injections
of polidocanol showed better results than curettage alone
(93% vs 85% healing) [32]. Repeated arterial embolizations
have also been reported with success rates of more than
80% [13]. Also, repeated injections of doxycycline, an anti-
biotic with some potential to inhibit matrix metalloprotein-
ases and angiogenesis was reported by Shiels et al. with a
healing rate of 94% in their series [33]. An overview com-
paring the results of different forms of therapy including
our own patients treated without Denosumab has recently
been published [34].
In GCT the interaction of RANK and RANKL is an im-
portant factor which regulates the giant cell formation and
progression of this tumor [35]. The pathophysiology of ABC
seems to be similar to this [29, 36]. Denosumab, which ef-
fectively blocks interaction between RANKL and RANK has
been approved for the treatment of osteoporosis, metastatic
bone disease, multiple myeloma and GCT [19, 37]. The use
of denosumab as an adjuvant treatment in patients with
GCT has shown a high rate of recalcification [38].
In ABC the first report of Denosumab treatment dates
back to 2012 [20]. Later 11 cases had been described in
9 studies. All patients showed regression of the lesion
and recalcification. This treatment effect rendered sur-
gery possible in two cases and the lesions were resected.
The reported follow-up was rather inhomogenous with
between 0 and 19months after cessation of Denosumab.
Local recurrence was described in just one case [21].
Kurucu et al. described 9 patients, 3 of them with surgical
or non-surgical pretreatment [19]. Denosumab was given
Fig. 2 a Radiograph of the right distal radius showing the typical metaepiphyseal exentric osteolysis of an ABC of bone. b: The lesions shows
typical fluid- fluid levels on T2-weighted TSE imaging with the patient in supine position. c: Local recurrence 3 months after curettage and bone
grafting. d, e: Radiographs 2 months (d) and 1 year (e) after surgery and starting of Denosumab therapy
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for 6–14months with median 15 doses. All patients were
free of symptoms after 3months. Radiological improvement
was evident in 8 cases. Follow-up time after the end of treat-
ment was 10–24months (median 15months). 2 patients
had further surgery, two other patients developed recurrence
(after 16months) or progressive disease and had renewed
treatment with Denosumab or surgery. In total, the authors
reported recurrence or progression in 4 of the 9 patients. In
addition, they observed severe hypercalcemia in two patients
10 and 24months after cessation of treatment.
Palmerini et al. reported 9 patients with Denosumab
treatment [18]. It is not clear from their publication how
many of the patients had any kind of prior therapy. Two
patients had surgery after Denosumab. All 9 patients
were classified as having sustained tumor control. At the
last follow-up 5 patients were still on Denosumab treat-
ment, 2 patients were disease-free after curettage and 2
patients are now 12 and 24months without Denosumab
and free of disease. No patient developed severe side
effects.
Denosumab is effective in ABC as it is in GCT of
bone. Our own results are similar to those described in
both previously published case series. It is clear from
those series as as well as from our own cases, that
follow-up time after cessation of treatment is a major
factor because recurrence, with some exceptions, needs
time to develop. In this respect, the published cases may
report better results than might be observed with longer
follow-up. In general, all published cases demonstrated a
clear clinical and radiological benefit of Denosumab in
more than two thirds of the patients.
A major factor is the age of the patients. ABC is a le-
sion in young adults or children. The published series
include patients as young as 2 years [19]. There is a risk
of retardation in growth and disturbed dental developing
with Denosumab not very well described up to now. The
currently available knowledge is mainly based on indi-
vidual treatment results in children suffering from fi-
brous dysplasia or osteogenesis imperfecta [39–43].
Most serious and as described also in one of our own pa-
tients is a rapid loss of the newly acquired bone caused by
rebound formation and activation of osteoclasts once treat-
ment is stopped, resulting in severe hypercalcemia [44, 45].
Other known adverse effects during denosumab therapy are
hypocalcemia, necrosis of the jaw, fatigue, muscular pain or
atypical femoral fractures if longer used [38].
Conclusions
Denosumab provides an additional non-invasive method
of treating ABCs in surgically critical locations such as
the spine or the pelvis. As shown here, it may also re-
duce the rate of local recurrence with adjuvant applica-
tion after intralesional surgery in aggressive lesions. Care
providers need to be aware that the use of Denosumab
in ABC is off-label and therefore requires a thorough
interdisciplinary discussion with the patient or his/her
family. The most common severe complication of Deno-
sumab, osteonecrosis of the jaw, has not been described
up to now in patients treated for ABC. But due to the
low age of many of the children, severe rebound hyper-
calcemia months after cessation of therapy remains a
considerable risk and implies that consequent laboratory
follow-up for at least 2 years be performed.
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